MUCINOUS ADENOCARCINOMA
Clinical trials for MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:15 UTC
-
New combo therapy shows promise for hard-to-treat colorectal cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to standard chemotherapy can help control or shrink metastatic colorectal cancer that has not responded to other treatments. About 80 adults with a specific type of colorectal cancer (pMMR/MSS) will receive this co…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated May 26, 2026 11:11 UTC